Microangiopathic Hemolytic Anemia and Thrombocytopenia in Patients With Cancer
Authors:
- 1 June 2016
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Oncology Practice
- Vol. 12 (6) , 523-530
Abstract
The unexpected occurrence of thrombotic microangiopathy (TMA), characterized by microangiopathic hemolytic anemia and thrombocytopenia, in a patient with cancer requires urgent diagnosis and appropriate management. TMA is a term used to describe multiple syndromes caused by microvascular thrombosis, including thrombotic thrombocytopenic purpura (TTP), Shiga toxin–mediated hemolytic uremic syndrome, and complement-mediated TMA. In patients with cancer, systemic microvascular metastases and bone marrow involvement can cause microangiopathic hemolytic anemia and thrombocytopenia. This occurs most often in patients with known metastatic cancer, but microangiopathic hemolytic anemia and thrombocytopenia may occur unexpectedly in patients without known metastatic disease or be the presenting features of undiagnosed cancer. TMA may also be caused by commonly used chemotherapy agents, either through dose-dependent toxicity or an acute immune-mediated reaction. These causes of TMA must be distinguished from TTP, which results from a severe deficiency of ADAMTS13 and is the most common cause of TMA among adults without cancer. The importance of this distinction is to avoid inappropriate use of plasma exchange, which is associated with major complications. Plasma exchange is the essential treatment for TTP, but it has no known benefit for patients with cancer-induced or drug-induced TMA. We will describe cancer-induced and drug-induced TMA using the experience of the Oklahoma TTP–Hemolytic Uremic Syndrome Registry and data from a systematic review of all published reports of drug-induced TMA. We will illustrate the principles of evaluation and management of these disorders with patients’ stories.Keywords
This publication has 23 references indexed in Scilit:
- Bone Marrow NecrosisAmerican Journal of Clinical Pathology, 2015
- Bone marrow necrosis discovered in a patient with suspected thrombotic thrombocytopenic purpuraAmerican Journal of Hematology, 2014
- Syndromes of Thrombotic MicroangiopathyNew England Journal of Medicine, 2014
- Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic SyndromeNew England Journal of Medicine, 2013
- Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: Comparison of incidence, demographic and clinical featuresPediatric Blood & Cancer, 2013
- Haemolytic uremic syndrome and gemcitabine: Jaundice is not always progression in cholangiocarcinomaActa Oncologica, 2012
- Disseminated Malignancy Misdiagnosed as Thrombotic Thrombocytopenic Purpura: A Report of 10 Patients and a Systematic Review of Published CasesThe Oncologist, 2007
- Occult systemic malignancy masquerading as thrombotic thrombocytopenic purpura-hemolytic uremic syndromeCommunity Oncology, 2005
- Disseminated Intravascular Coagulation in Solid Tumors: Clinical and Pathologic StudyThrombosis and Haemostasis, 2001
- Reassessing the hemostatic disorder associated with acute promyelocytic leukemia [see comments]Blood, 1992